Related Experiment Video

Updated: Aug 19, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

PIK3CA mutations in advanced ovarian carcinomas

Yun Wang1, Aslaug Helland, Ruth Holm

  • 1Department of Gynecologic Oncology, The Norwegian Radium Hospital, N-0310, Oslo, Norway.

Human Mutation
|February 16, 2005
PubMed

Insights

Activating mutations in the PIK3CA gene were found in advanced ovarian cancers. These PIK3CA gene mutations appear more frequent in rare mucinous and clear cell ovarian tumor types.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The PIK3CA gene encodes a key enzyme in the phosphatidylinositol 3-kinase (PI3K) family, crucial for cell signaling pathways regulating proliferation, survival, and transformation.
  • Somatic activating mutations in PIK3CA have been implicated in the development and progression of various human cancers.
  • The PI3K/AKT signaling pathway is a critical regulator of cellular functions, and its dysregulation contributes to oncogenesis.

Purpose of the Study:

  • To investigate the frequency and spectrum of PIK3CA gene mutations in exon 9 and exon 20 within a cohort of advanced ovarian carcinomas.
  • To explore potential correlations between PIK3CA mutations and specific histological subtypes of ovarian cancer, particularly rare types.

Main Methods:

  • Direct sequencing was employed to analyze PIK3CA gene mutations in exons 9 and 20.
  • A cohort of 109 advanced ovarian carcinoma samples was utilized for the mutation analysis.

Main Results:

  • Activating missense mutations in the PIK3CA gene were identified in 4 out of 109 (approximately 3.7%) advanced ovarian carcinomas.
  • One additional non-coding variant was detected, resulting in no amino acid change in the PIK3CA protein.
  • Notably, two of the four tumors harboring PIK3CA mutations were of the mucinous and clear cell histological subtypes, suggesting a potential enrichment of these mutations in rare ovarian cancer types.

Conclusions:

  • PIK3CA gene mutations occur in a subset of advanced ovarian carcinomas.
  • The findings suggest that PIK3CA mutations may be more prevalent in rare histological subtypes of ovarian cancer, such as mucinous and clear cell carcinomas.
  • Further research into PIK3CA alterations in specific ovarian cancer subtypes could inform targeted therapeutic strategies.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...